Grove Biopharma in the News

Protein-like polymers induce protein degradation

Grove Biopharma Reports Preclinical Study in Nature Communications Demonstrating a Novel Approach to MYC and KRAS Degradation

Heterobifunctional proteomimetic polymers for targeted degradation of MYC and KRAS

Geoffrey Duyk, Grove Biopharma CEO, on Polymer Breakthroughs, Intractable Targets & Biotech's Future

Grove Biopharma to Participate in Materials Biology Symposium at ACS Fall 2025 Scientific Meeting

Injectable Protein-Like Polymers Protect Rodent Heart After Myocardial Infarction

New Therapy Could Help Heart Tissue Heal After Heart Attack

Protein-Like Polymers Targeting Keap1/Nrf2 as Therapeutics for Myocardial Infarction

Grove Biopharma launches to develop therapeutic protein-like polymers

Building Biotech at the Interface: Geoff Duyk on Genomics, Platforms, and Grove Biopharma

Grove Biopharma triples footprint in Fulton Market after $30 million funding round

Grove Biopharma raises $30 million

Chicago startup Grove Biopharma nabs $30M Series A

Grove Biopharma Closes $30 Million Series A Financing to Advance Bionic Biologics™, a New Therapeutic Modality